Patents by Inventor Martine Van Vugt

Martine Van Vugt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160130362
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: October 8, 2015
    Publication date: May 12, 2016
    Inventors: Michel DE WEERS, Yvo GRAUS, Judith OPRINS, Paul PARREN, Jan VAN DE WINKEL, Martine VAN VUGT
  • Patent number: 9187565
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: November 17, 2015
    Assignee: GENMAB A/S
    Inventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
  • Publication number: 20150231235
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: December 10, 2014
    Publication date: August 20, 2015
    Inventors: Jan VAN DE WINKEL, Paul PARREN, Yvo GRAUS, Judith OPRINS, Michel DE WEERS, Martine VAN VUGT, Ole BAADSGAARD, D.M.Sc., Steen LISBY
  • Patent number: 9102733
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: August 11, 2015
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Patent number: 9040050
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: May 26, 2015
    Assignee: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Yvo Graus, Judith Oprins, Michel De Weers, Martine Van Vugt, Ole Baadsgaard, Steen Lisby
  • Publication number: 20110099647
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: September 21, 2010
    Publication date: April 28, 2011
    Applicant: GENMAB A/S
    Inventors: Michel DE WEERS, Yvo GRAUS, Judith OPRINS, Paul PARREN, Jan VAN DE WINKEL, Martine VAN VUGT
  • Publication number: 20110086026
    Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
    Type: Application
    Filed: July 26, 2010
    Publication date: April 14, 2011
    Inventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
  • Publication number: 20110070239
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Application
    Filed: December 1, 2010
    Publication date: March 24, 2011
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Patent number: 7868141
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 11, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
  • Patent number: 7829673
    Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: November 9, 2010
    Assignee: Genmab A/S
    Inventors: Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt
  • Patent number: 7824684
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: November 2, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Patent number: 7807158
    Abstract: The instant specification discloses an antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.
    Type: Grant
    Filed: January 3, 2006
    Date of Patent: October 5, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
  • Publication number: 20100209423
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Application
    Filed: April 27, 2010
    Publication date: August 19, 2010
    Inventors: YVO GRAUS, JACQUES HIMBER, MIRANDA JANSEN-MOLENAAR, DOROTHEE KLING, ERHARD KOPETZKI, PAUL PARREN, FRANK REBERS, BEAT STEINER, ANNE STERN, PAMELA STREIN, KAY-GUNNAR STUBENRAUCH, JAN VAN DE WINKEL, MARTINE VAN VUGT
  • Patent number: 7754867
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: July 13, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Publication number: 20100166740
    Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.
    Type: Application
    Filed: December 5, 2008
    Publication date: July 1, 2010
    Inventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van de Winkel, Martine Van Vugt
  • Publication number: 20100092489
    Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non- corticosteroid chemotherapeutic agent.
    Type: Application
    Filed: September 26, 2007
    Publication date: April 15, 2010
    Applicant: GENMAB A/S
    Inventors: Jan Van De Winkel, Paul Parren, Yvo Graus, Judith Oprins, Michel De Weers, Martine Van Vugt, Ole Baadsgaard, Steen Lisby
  • Publication number: 20090311779
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Application
    Filed: June 10, 2009
    Publication date: December 17, 2009
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Patent number: RE43568
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: August 7, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan Van de Winkel, Martine Van Vugt
  • Patent number: RE44359
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: July 9, 2013
    Assignee: Hoffmann-La Roche Inc
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
  • Patent number: RE44389
    Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: July 23, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Braemer, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt